ALNYLAM PHARMACEUTICALS, INC.

• ALNYLAM PHARMACEUTICALS, INC. $2,960,000 In-house, the client's own filings · 7 filings
• SPLITOAK STRATEGIES LLC $420,000 Outside firm · 7 filings
• TIBER CREEK GROUP $420,000 Outside firm · 7 filings
• TODD STRATEGY GROUP $420,000 Outside firm · 7 filings
• LMH STRATEGIC SOLUTIONS $350,000 Outside firm · 8 filings
• CAPITOL COUNSEL LLC $230,000 Outside firm · 9 filings
• THE MCMANUS GROUP $140,000 Outside firm · 3 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

• H.R. 1672
  Maintaining Investments in New Innovation Act
  33 filings
• H.R. 946
  ORPHAN Cures Act
  22 filings
• S. 1862
  ORPHAN Cures Act
  14 filings
• H.R. 4993
  Joe Fiandra Access to Home Infusion Act of 2025
  5 filings

• 2026 $2,160,000 18 filings
• 2025 $2,780,000 30 filings

• Medicare/Medicaid 39
• Medical/Disease Research/Clinical Labs 9
• Trade (domestic/foreign) 7
• Pharmacy 6
• Health Issues 1
• Veterans 1

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

• HOUSE OF REPRESENTATIVES 41
• SENATE 41
• Food & Drug Administration (FDA) 7
• Executive Office of the President (EOP) 6
• Health & Human Services, Dept of (HHS) 6